Evidence map›Paper›PMID 33484569›Full record

ArticleJournal of the National Cancer Institute2021

Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.

Christopher J Cadham, Pianpian Cao, Jinani Jayasekera, Kathryn L Taylor, David T Levy, Jihyoun Jeon, Elena B Elkin, Kristie L Foley, Anne Joseph, Chung Yin Kong and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03200236 (Integrating Evidence-Based Smoking Cessation Interventions Into Lung Cancer Screening Programs), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03200236 phase3completednot on this map

Integrating Evidence-Based Smoking Cessation Interventions Into Lung Cancer Screening Programs: A Randomized Trial

TypeinterventionalSponsorGeorgetown UniversityRan2017 to 2022Enrolled1,114ConditionsSmoking, Tobacco, Tobacco-Related Carcinoma, Tobacco Use, Lung Cancer ScreeningArmsIntensive Telephone Counseling (8 sessions) with nicotine replacement, Usual Care: Telephone counseling (3 sessions) with nicotine replacement
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Predictors of Cessation Readiness among Cigarette Smokers Presenting for Low-Dose CT Lung Cancer Screening in Community Settings (WF-20817CD).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Updates in Lung Cancer Screening: A Decade of Evidence.Seminars in respiratory and critical care medicine · 2025
    Review
  17. Article
  18. Article
  19. Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025
    Article
  20. The impact of smoking on lung cancer patients.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Christopher J CadhamDepartment of Oncology, Georgetown University School of Medicine, Washington, DC, USA.ORCID 0000-0001-9531-2733
Pianpian CaoDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.ORCID 0000-0001-8886-9672
Jinani JayasekeraDepartment of Oncology, Georgetown University School of Medicine, Washington, DC, USA.ORCID 0000-0001-9212-7225
Kathryn L TaylorDepartment of Oncology, Georgetown University School of Medicine, Washington, DC, USA.
David T LevyDepartment of Oncology, Georgetown University School of Medicine, Washington, DC, USA.ORCID 0000-0001-5280-3612
Jihyoun JeonDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.ORCID 0000-0001-7003-3412
Elena B ElkinDepartment of Health Policy and Management at Columbia University Mailman School of Public Health, New York, NY, USA.
Kristie L FoleyDepartment of Implementation Science, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Anne JosephDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Chung Yin KongDivision of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-6431-7830
Jennifer A MinnixDepartment of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6017-6735
Nancy A RigottiDepartment of Medicine and Mongan Institute, Tobacco Research and Treatment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Benjamin A TollDepartment of Public Health Sciences and Psychiatry, Medical University of South Carolina, Charleston, SC, USA.
Steven B ZeliadtDepartment of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.
Rafael MezaDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.ORCID 0000-0002-1076-5037
Jeanne MandelblattDepartment of Oncology, Georgetown University School of Medicine, Washington, DC, USA.ORCID 0000-0002-2490-005X
CISNET-SCALE Collaboration

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
Comparative Modeling: Informing Breast Cancer Control Practice and PolicyU01CA199218 · NCI · GEORGETOWN UNIVERSITY · PI BERRY, DONALD A, DE KONING, HARRY J · 2015 to 2019
$9.0M
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment InterventionsU01CA253858 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2020 to 2025
$8.4M
Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
Bio-behavioral Research At The Intersection of Cancer and AgingR35CA197289 · NCI · GEORGETOWN UNIVERSITY · PI MANDELBLATT, JEANNE · 2015 to 2021
$6.2M
Integrating Evidence-Based Smoking Cessation Interventions into Lung Cancer Screening Programs: A Randomized TrialR01CA207228 · NCI · GEORGETOWN UNIVERSITY · PI TAYLOR, KATHRYN L · 2016 to 2020
$3.5M
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung CancerR01CA207078 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CINCIRIPINI, PAUL MICHAEL · 2016 to 2021
$3.3M
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening ProgramsR01CA207229 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TOLL, BENJAMIN ANDREW · 2016 to 2022
$3.0M
A Simulation Model-based Framework to Support Oncology Guidelines and PracticeK99CA241397 · NCI · GEORGETOWN UNIVERSITY · PI JAYASEKERA, JINANI · 2020 to 2021
$351k
HSRD VA I01 HX002172NCI NIH HHS K99 CA241397NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA207078NCI NIH HHS R01 CA207228NCI NIH HHS R01 CA207229NCI NIH HHS R35 CA197289NCI NIH HHS U01 CA199218NCI NIH HHS U01 CA199284NCI NIH HHS U01 CA253858NCI NIH HHS UG1 CA189824
6 · The paper itself

Abstract

backgroundGuidelines recommend offering cessation interventions to smokers eligible for lung cancer screening, but there is little data comparing specific cessation approaches in this setting. We compared the benefits and costs of different smoking cessation interventions to help screening programs select specific cessation approaches.

methodsWe conducted a societal-perspective cost-effectiveness analysis using a Cancer Intervention and Surveillance Modeling Network model simulating individuals born in 1960 over their lifetimes. Model inputs were derived from Medicare, national cancer registries, published studies, and micro-costing of cessation interventions. We modeled annual lung cancer screening following 2014 US Preventive Services Task Force guidelines plus cessation interventions offered to current smokers at first screen, including pharmacotherapy only or pharmacotherapy with electronic and/or web-based, telephone, individual, or group counseling. Outcomes included lung cancer cases and deaths, life-years saved, quality-adjusted life-years (QALYs) saved, costs, and incremental cost-effectiveness ratios.

resultsCompared with screening alone, all cessation interventions decreased cases of and deaths from lung cancer. Compared incrementally, efficient cessation strategies included pharmacotherapy with either web-based cessation ($555 per QALY), telephone counseling ($7562 per QALY), or individual counseling ($35 531 per QALY). Cessation interventions continued to have costs per QALY well below accepted willingness to pay thresholds even with the lowest intervention effects and was more cost-effective in cohorts with higher smoking prevalence.

conclusionAll smoking cessation interventions delivered with lung cancer screening are likely to provide benefits at reasonable costs. Because the differences between approaches were small, the choice of intervention should be guided by practical concerns such as staff training and availability.

Indexed as

Lung NeoplasmsSmoking CessationAgedCost-Benefit AnalysisEarly Detection of CancerHumansMedicareMiddle AgedQuality-Adjusted Life YearsUnited States

Identifiers

PMID33484569
PMCPMC8502465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.